Jefferies Financial Group’s Travere Therapeutics TVTX Stock Holding History

Jefferies Financial Group’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$144K	Buy	4,837 +1,837	+61%	+$54.9K	﹤0.01%	1564
2025 Q4	$115K	Sell	3,000 -1,000	-25%	-$32.5K	﹤0.01%	1690
2025 Q3	$95.6K	Buy	+4,000	New	+$75.2K	﹤0.01%	1345
2024 Q3	–	Sell	-59,300	Closed	-$487K	–	1777
2024 Q2	$487K	Hold	59,300	–	–	0.01%	979
2024 Q1	$457K	Buy	+59,300	New	+$500K	﹤0.01%	1088
2023 Q2	–	Sell	-15,000	Closed	-$337K	–	2010
2023 Q1	$337K	Buy	+15,000	New	+$319K	﹤0.01%	1200

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jefferies Financial Group's TVTX Position: Q1 2026 in Review

Jefferies Financial Group increased its Travere Therapeutics (TVTX) stake by 61% in Q1 2026, buying an estimated $54.9K and bringing the position to 4,837 shares worth $144K. The position accounts for ﹤0.01% of the portfolio, ranked #1564.

Jefferies Financial Group first reported a position in TVTX in Q1 2023 and has held it in 6 quarters since. The position peaked at $487K in Q2 2024. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Jefferies Financial Group held 4,837 shares of Travere Therapeutics worth $144K as of Q1 2026.
Jefferies Financial Group bought 1,837 Travere Therapeutics shares in Q1 2026, an estimated $54.9K.
Travere Therapeutics made up ﹤0.01% of Jefferies Financial Group's portfolio in Q1 2026, its #1564 holding.
Jefferies Financial Group first reported a position in Travere Therapeutics in Q1 2023 and has held it in 6 quarters since.
Jefferies Financial Group's Travere Therapeutics position peaked at $487K in Q2 2024.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.